BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Goldaracena N, Gorgen A, Sapisochin G. Current status of liver transplantation for cholangiocarcinoma. Liver Transpl. 2018;24:294-303. [PMID: 29024405 DOI: 10.1002/lt.24955] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 9.5] [Reference Citation Analysis]
Number Citing Articles
1 Jeong S, Sha M, Xia Q. Current status of liver transplantation for cholangiocarcinoma. Liver Transpl 2018;24:440. [PMID: 29125693 DOI: 10.1002/lt.24974] [Reference Citation Analysis]
2 Zanetto A, Shalaby S, Gambato M, Germani G, Senzolo M, Bizzaro D, Russo FP, Burra P. New Indications for Liver Transplantation. J Clin Med 2021;10:3867. [PMID: 34501314 DOI: 10.3390/jcm10173867] [Reference Citation Analysis]
3 Dondossola D, Ghidini M, Grossi F, Rossi G, Foschi D. Practical review for diagnosis and clinical management of perihilar cholangiocarcinoma. World J Gastroenterol 2020; 26(25): 3542-3561 [PMID: 32742125 DOI: 10.3748/wjg.v26.i25.3542] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 9] [Article Influence: 7.5] [Reference Citation Analysis]
4 Serifis N, Tsilimigras DI, Cloonan DJ, Pawlik TM. Challenges and Opportunities for Treating Intrahepatic Cholangiocarcinoma. Hepat Med 2021;13:93-104. [PMID: 34754247 DOI: 10.2147/HMER.S278136] [Reference Citation Analysis]
5 Gorgen A, Goldaracena N, Zhang W, Sapisochin G. Intrahepatic cholangiocarcinoma, are we making progress? Hepatobiliary Surg Nutr 2018;7:127-9. [PMID: 29744342 DOI: 10.21037/hbsn.2017.12.14] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
6 Herrero Torres MA, Dominguez Bastante M, Molina Raya A, Palomo Lopez I, Santoyo Villalba J, Villegas Herrera MT, Becerra Massare A, Brea Gomez E, Zambudio Carroll N, Villar Del Moral JM. Cholangiocarcinoma, 10-Year Survival After Liver Transplantation: A Case Report. Transplant Proc 2020;52:592-3. [PMID: 32057500 DOI: 10.1016/j.transproceed.2019.12.030] [Reference Citation Analysis]
7 Rizzo A, Brandi G. Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review. Cancer Treat Res Commun 2021;27:100354. [PMID: 33756174 DOI: 10.1016/j.ctarc.2021.100354] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
8 Liu ZX, Li LM, Sun HL, Liu SM. Link Between m6A Modification and Cancers. Front Bioeng Biotechnol 2018;6:89. [PMID: 30062093 DOI: 10.3389/fbioe.2018.00089] [Cited by in Crossref: 42] [Cited by in F6Publishing: 52] [Article Influence: 10.5] [Reference Citation Analysis]
9 Safarpour AR, Askari H, Ejtehadi F, Azarnezhad A, Raeis-Abdollahi E, Tajbakhsh A, Abazari MF, Tarkesh F, Shamsaeefar A, Niknam R, Sivandzadeh GR, Lankarani KB, Ejtehadi F. Cholangiocarcinoma and liver transplantation: What we know so far? World J Gastrointest Pathophysiol 2021; 12(5): 84-105 [PMID: 34676129 DOI: 10.4291/wjgp.v12.i5.84] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Voesch S, Bitzer M, Malek N. [Clinical relevance of the new S3 guideline on hepatocellular carcinoma and biliary tract cancer for practitioners]. Radiologe 2022. [PMID: 35147708 DOI: 10.1007/s00117-022-00970-3] [Reference Citation Analysis]
11 Saffioti F, Mavroeidis VK. Review of incidence and outcomes of treatment of cholangiocarcinoma in patients with primary sclerosing cholangitis. World J Gastrointest Oncol 2021; 13(10): 1336-1366 [PMID: 34721770 DOI: 10.4251/wjgo.v13.i10.1336] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Manekeller S, Kalff JC. [Treatment approach for gall bladder and extrahepatic bile duct cancer]. Chirurg 2018;89:880-6. [PMID: 30094707 DOI: 10.1007/s00104-018-0704-4] [Reference Citation Analysis]
13 Sun JM, Xu HT, Zhao L, Zhang YB, Kang PC, Song ZF, Liu HS, Cui YF. Induction of cell-cycle arrest and apoptosis in human cholangiocarcinoma cells by pristimerin. J Cell Biochem 2019. [PMID: 30825242 DOI: 10.1002/jcb.28485] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
14 Cillo U, De Carlis L, Del Gaudio M, De Simone P, Fagiuoli S, Lupo F, Tisone G, Volpes R. Immunosuppressive regimens for adult liver transplant recipients in real-life practice: consensus recommendations from an Italian Working Group. Hepatol Int 2020;14:930-43. [PMID: 33099753 DOI: 10.1007/s12072-020-10091-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
15 Hafeez Bhatti AB, Tahir R, Qureshi NR, Mamoon N, Khan NY, Zia HH. Living donor liver transplantation for intra hepatic cholangiocarcinoma. Ann Med Surg (Lond) 2020;57:82-4. [PMID: 32728435 DOI: 10.1016/j.amsu.2020.07.028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Jaradat D, Bagias G, Lorf T, Tokat Y, Obed A, Oezcelik A. Liver transplantation for combined hepatocellular-cholangiocarcinoma: Outcomes and prognostic factors for mortality. A multicenter analysis. Clin Transplant. 2021;35:e14094. [PMID: 32970878 DOI: 10.1111/ctr.14094] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Li F, Peiris MN, Donoghue DJ. Functions of FGFR2 corrupted by translocations in intrahepatic cholangiocarcinoma. Cytokine Growth Factor Rev 2020;52:56-67. [PMID: 31899106 DOI: 10.1016/j.cytogfr.2019.12.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
18 Machairas N, Stamopoulos P, Kostakis ID, Garoufalia Z, Paspala A, Tsaparas P, Sotiropoulos GC. Mixed Hepatocellular Cholangiocarcinoma: A Review of Long-Term Outcomes Following Liver Transplantation. Transplant Proc 2019;51:437-9. [PMID: 30879560 DOI: 10.1016/j.transproceed.2019.01.073] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
19 Kong J, Shen S, Zhang Z, Wang W. Identification of hub genes and pathways in cholangiocarcinoma by coexpression analysis. Cancer Biomark 2020;27:505-17. [PMID: 32116234 DOI: 10.3233/CBM-190038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Moeckli B, Ivanics T, Claasen M, Toso C, Sapisochin G. Recent developments and ongoing trials in transplant oncology. Liver Int 2020;40:2326-44. [PMID: 33021344 DOI: 10.1111/liv.14621] [Reference Citation Analysis]
21 Steenstraten IC, Sebib Korkmaz K, Trivedi PJ, Inderson A, van Hoek B, Rodriguez Girondo MDM, Maljaars PWJ. Systematic review with meta-analysis: risk factors for recurrent primary sclerosing cholangitis after liver transplantation. Aliment Pharmacol Ther. 2019;49:636-643. [PMID: 30740723 DOI: 10.1111/apt.15148] [Cited by in Crossref: 31] [Cited by in F6Publishing: 18] [Article Influence: 10.3] [Reference Citation Analysis]
22 Krasnodębski M, Grąt M, Jastrzębski M, Szczęśniak M, Morawski M, Zając K, Patkowski W, Zieniewicz K. Unsatisfactory Long-term Results of Liver Transplant in Patients With Intrahepatic Cholangiocarcinoma. Transplant Proc 2020;52:2463-7. [PMID: 32327261 DOI: 10.1016/j.transproceed.2020.02.095] [Reference Citation Analysis]
23 Sha M, Jeong S, Xia Q. Analysis of Liver Resection Versus Liver Transplantation on Outcome of Small Intrahepatic Cholangiocarcinoma and Combined Hepatocellular-Cholangiocarcinoma in the Setting of Cirrhosis. Liver Transpl 2020;26:1202-3. [PMID: 32198964 DOI: 10.1002/lt.25758] [Reference Citation Analysis]
24 Song P, Midorikawa Y, Nakayama H, Higaki T, Moriguchi M, Aramaki O, Yamazaki S, Aoki M, Teramoto K, Takayama T. Patients' prognosis of intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma after resection. Cancer Med. 2019;8:5862-5871. [PMID: 31407490 DOI: 10.1002/cam4.2495] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
25 Cadamuro M, Lasagni A, Lamarca A, Fouassier L, Guido M, Sarcognato S, Gringeri E, Cillo U, Strazzabosco M, Marin JJ, Banales JM, Fabris L. Targeted therapies for extrahepatic cholangiocarcinoma: preclinical and clinical development and prospects for the clinic. Expert Opin Investig Drugs 2021;30:377-88. [PMID: 33622120 DOI: 10.1080/13543784.2021.1880564] [Reference Citation Analysis]
26 Ren A, Li Z, Zhang X, Deng R, Ma Y. A model for predicting post-liver transplantation recurrence in intrahepatic cholangiocarcinoma recipients. J Gastrointest Oncol 2020;11:1283-90. [PMID: 33457001 DOI: 10.21037/jgo-20-209] [Reference Citation Analysis]
27 Rojas-Pintor KP, Arizmendi-Villarreal MA, Aparicio-Salas JE, Moreno-Peña DP, Hernández-Barajas D, Cordero-Pérez P, Muñoz-Espinosa LE. Differences in the presentation and treatment of primary liver tumors at a hepatology center and an oncology center. Rev Gastroenterol Mex (Engl Ed) 2021:S0375-0906(21)00002-1. [PMID: 33676785 DOI: 10.1016/j.rgmx.2020.08.005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
28 Entezari P, Riaz A. Intrahepatic Cholangiocarcinoma.Semin Intervent Radiol. 2020;37:475-483. [PMID: 33328703 DOI: 10.1055/s-0040-1719188] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
29 Chahal D, Shamatutu C, Salh B, Davies J. The impact of primary sclerosing cholangitis or inflammatory bowel disease on cholangiocarcinoma phenotype, therapy, and survival. JGH Open 2020;4:1128-34. [PMID: 33319047 DOI: 10.1002/jgh3.12405] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
30 Zhou J, Nie W, Yuan J, Zhang Z, Mi L, Wang C, Huang R. GSG2 knockdown suppresses cholangiocarcinoma progression by regulating cell proliferation, apoptosis and migration. Oncol Rep 2021;45:91. [PMID: 33846801 DOI: 10.3892/or.2021.8042] [Reference Citation Analysis]
31 Romine MM, White J. Role of Transplant in Biliary Disease. Surgical Clinics of North America 2019;99:387-401. [DOI: 10.1016/j.suc.2018.12.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
32 Lee TC, Morris MC, Patel SH, Shah SA. Expanding the Surgical Pool for Hepatic Resection to Treat Biliary and Primary Liver Tumors. Surg Oncol Clin N Am 2019;28:763-82. [PMID: 31472918 DOI: 10.1016/j.soc.2019.06.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
33 Bitzer M, Voesch S, Albert J, Bartenstein P, Bechstein W, Blödt S, Brunner T, Dombrowski F, Evert M, Follmann M, La Fougère C, Freudenberger P, Geier A, Gkika E, Götz M, Hammes E, Helmberger T, Hoffmann RT, Hofmann WP, Huppert P, Kautz A, Knötgen G, Körber J, Krug D, Lammert F, Lang H, Langer T, Lenz P, Mahnken A, Meining A, Micke O, Nadalin S, Nguyen HP, Ockenga J, Oldhafer K, Paprottka P, Paradies K, Pereira P, Persigehl T, Plauth M, Plentz R, Pohl J, Riemer J, Reimer P, Ringwald J, Ritterbusch U, Roeb E, Schellhaas B, Schirmacher P, Schmid I, Schuler A, von Schweinitz D, Seehofer D, Sinn M, Stein A, Stengel A, Steubesand N, Stoll C, Tannapfel A, Taubert A, Trojan J, van Thiel I, Tholen R, Vogel A, Vogl T, Vorwerk H, Wacker F, Waidmann O, Wedemeyer H, Wege H, Wildner D, Wittekind C, Wörns MA, Galle P, Malek N. S3-Leitlinie – Diagnostik und Therapie biliärer Karzinome. Z Gastroenterol 2022;60:e186-227. [PMID: 35148560 DOI: 10.1055/a-1589-7854] [Reference Citation Analysis]
34 Yilmaz S, Carr BI, Akbulut S. Can the Limits of Liver Transplantation Be Expanded in Perihilar Cholangiocarcinoma? J Gastrointest Cancer 2021. [PMID: 34738188 DOI: 10.1007/s12029-021-00735-6] [Reference Citation Analysis]
35 Goldaracena N, Gorgen A, Sapisochin G. Reply. Liver Transpl 2018;24:441. [PMID: 29125672 DOI: 10.1002/lt.24971] [Reference Citation Analysis]
36 Ernani L, Martino RB, Andraus W, Fernandes ESM, Mello FPT, Andrade R, Pimentel LS, Haddad LBP, Coelho FF, Herman P, D'Albuquerque LAC. PROTOCOL FOR LIVER TRANSPLANTATION IN HILAR CHOLANGIOCARCINOMA. Arq Bras Cir Dig 2022;34:e1618. [PMID: 35019130 DOI: 10.1590/0102-672020210002e1618] [Reference Citation Analysis]
37 Ness JR, Molvar C. Radioembolization of Intrahepatic Cholangiocarcinoma: Patient Selection, Outcomes, and Competing Therapies. Semin Intervent Radiol 2021;38:438-44. [PMID: 34629711 DOI: 10.1055/s-0041-1735526] [Reference Citation Analysis]
38 Zhu Y, Song J, Xu X, Tan Y, Yang J. Safety and feasibility of laparoscopic liver resection for patients with large or multiple intrahepatic cholangiocarcinomas: A propensity score based case-matched analysis from a single institute. Medicine (Baltimore) 2019;98:e18307. [PMID: 31804378 DOI: 10.1097/MD.0000000000018307] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
39 Väli T, Tein A, Uksov A. Liver transplantation for hepatic tumors: A small center experience. Transplantation Reports 2019;4:100033. [DOI: 10.1016/j.tpr.2019.100033] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
40 Panayotova GG, Paterno F, Guarrera JV, Lunsford KE. Liver Transplantation for Cholangiocarcinoma: Insights into the Prognosis and the Evolving Indications. Curr Oncol Rep. 2020;22:49. [PMID: 32297105 DOI: 10.1007/s11912-020-00910-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
41 Beal EW, Cloyd JM, Pawlik TM. Surgical Treatment of Intrahepatic Cholangiocarcinoma: Current and Emerging Principles. J Clin Med 2020;10:E104. [PMID: 33396821 DOI: 10.3390/jcm10010104] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
42 Hewitt DB, Brown ZJ, Pawlik TM. Surgical management of intrahepatic cholangiocarcinoma. Expert Rev Anticancer Ther 2021;:1-12. [PMID: 34730474 DOI: 10.1080/14737140.2022.1999809] [Reference Citation Analysis]
43 Hang H, Jeong S, Sha M, Kong D, Xi Z, Tong Y, Xia Q. Cholangiocarcinoma: anatomical location-dependent clinical, prognostic, and genetic disparities. Ann Transl Med 2019;7:744. [PMID: 32042760 DOI: 10.21037/atm.2019.12.37] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
44 Kimbrough CW, Cloyd JM, Pawlik TM. Surgical approaches for the treatment of perihilar cholangiocarcinoma. Expert Review of Anticancer Therapy 2018;18:673-83. [DOI: 10.1080/14737140.2018.1473039] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
45 Ziogas IA, Hickman LA, Matsuoka LK, Izzy M, Montenovo MI, Rega SA, Feurer ID, Alexopoulos SP. Comparison of Wait-List Mortality Between Cholangiocarcinoma and Hepatocellular Carcinoma Liver Transplant Candidates. Liver Transpl. 2020;26:1112-1120. [PMID: 32475062 DOI: 10.1002/lt.25807] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
46 Finotti M, Auricchio P, Vitale A, Gringeri E, Cillo U. Liver transplantation for rare liver diseases and rare indications for liver transplant. Transl Gastroenterol Hepatol 2021;6:27. [PMID: 33824931 DOI: 10.21037/tgh-19-282] [Reference Citation Analysis]
47 Rojas-Pintor KP, Arizmendi-Villarreal MA, Aparicio-Salas JE, Moreno-Peña DP, Hernández-Barajas D, Cordero-Pérez P, Muñoz-Espinosa LE. Differences in the presentation and treatment of primary liver tumors at a hepatology center and an oncology center. Rev Gastroenterol Mex (Engl Ed) 2021:S2255-534X(21)00080-3. [PMID: 34384724 DOI: 10.1016/j.rgmxen.2021.07.006] [Reference Citation Analysis]
48 Ren A, Li Z, Cheng P, Zhang X, Deng R, Ma Y. Systemic Immune-Inflammation Index Is a Prognostic Predictor in Patients with Intrahepatic Cholangiocarcinoma Undergoing Liver Transplantation. Mediators Inflamm 2021;2021:6656996. [PMID: 33628115 DOI: 10.1155/2021/6656996] [Reference Citation Analysis]